LYRA
Lyra Therapeutics Inc
NASDAQ: LYRA · HEALTHCARE · BIOTECHNOLOGY
$0.71
+0.00% today
Updated 2026-04-30
Market cap
$870050.00
P/E ratio
—
P/S ratio
1.45x
EPS (TTM)
$-22.90
Dividend yield
—
52W range
$0 – $34
Volume
0.1M
Lyra Therapeutics Inc (LYRA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-25,032.00%
ROE
-404.50%
ROA
-33.10%
Debt/equity
-7.25x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2018 | $1.24M | $-6.03M | 100.00% | -583.52% | -484.65% |
| 2019 | $0.00 | $-16.31M | — | — | — |
| 2020 | $0.00 | $-22.13M | — | — | — |
| 2021 | $285000.00 | $-42.41M | 100.00% | -15,303.51% | -14,880.70% |
| 2022 | $1.36M | $-55.28M | 100.00% | -4,131.03% | -4,055.61% |
| 2023 | $1.56M | $-62.68M | 100.00% | -4,308.09% | -4,023.11% |
| 2024 | $1.53M | $-93.44M | 100.00% | -6,280.83% | -6,090.94% |